These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15156965)

  • 61. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.
    Dhillon S
    Target Oncol; 2015 Mar; 10(1):153-70. PubMed ID: 25637458
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
    Nishino K; Imamura F; Morita S; Mori M; Komuta K; Kijima T; Namba Y; Kumagai T; Yamamoto S; Tachibana I; Nakazawa Y; Uchida J; Minami S; Takahashi R; Yano Y; Okuyama T; Kumanogoh A
    Lung Cancer; 2013 Nov; 82(2):299-304. PubMed ID: 24018023
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Gefitinib for non-small-cell lung cancer treatment.
    D'Incecco A; Cappuzzo F
    Expert Opin Drug Saf; 2011 Nov; 10(6):987-96. PubMed ID: 21905963
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
    Chiu CH; Tsai CM; Chen YM; Chiang SC; Liou JL; Perng RP
    Lung Cancer; 2005 Jan; 47(1):129-38. PubMed ID: 15603863
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
    Cella D; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Heyes A; Ochs JS; Wolf MK; Kay AC; Kris MG; Natale RB
    J Clin Oncol; 2005 May; 23(13):2946-54. PubMed ID: 15699477
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].
    Zhao YY; Zhang Y; Zhao HY; Wu JX; Jiang W; Xue C; Zhang L
    Ai Zheng; 2009 Jun; 28(6):626-31. PubMed ID: 19635201
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.
    Rossi A; Maione P; Del Gaizo F; Guerriero C; Castaldo V; Gridelli C
    Lung Cancer; 2005 Mar; 47(3):421-3. PubMed ID: 15713526
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
    Kobayashi H; Sato K; Niioka T; Miura H; Ito H; Miura M
    Clin Lung Cancer; 2015 Jul; 16(4):274-81. PubMed ID: 25554506
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Gefitinib: an adverse effects profile.
    Cersosimo RJ
    Expert Opin Drug Saf; 2006 May; 5(3):469-79. PubMed ID: 16610973
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
    William WN; Gold KA; Kim ES
    Ann Oncol; 2009 Sep; 20(9):1455-1457. PubMed ID: 19704160
    [No Abstract]   [Full Text] [Related]  

  • 72. Clinical efficacy and toxiciy of gefitinib in patients with lung cancer.
    Mitsui H; Nakajima J; Maruyama T; Hanajiri K; Omata M
    Lancet; 2003 Jun; 361(9373):1993. PubMed ID: 12801776
    [No Abstract]   [Full Text] [Related]  

  • 73. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
    Rabinowits G; Herchenhorn D; Rabinowits M; Weatge D; Torres W
    Anticancer Drugs; 2003 Sep; 14(8):665-8. PubMed ID: 14501391
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?
    Okamoto I; Suga M
    Intern Med; 2003 Oct; 42(10):926-7. PubMed ID: 14606701
    [No Abstract]   [Full Text] [Related]  

  • 75. More haste, less speed.
    Lancet Oncol; 2003 Jun; 4(6):325. PubMed ID: 12788389
    [No Abstract]   [Full Text] [Related]  

  • 76. Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
    Goto Y; Hojo M; Takeda Y; Kobayashi N; Kudo K
    Med Oncol; 2010 Sep; 27(3):753-5. PubMed ID: 19653137
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selection bias, phase II trials, and the FDA accelerated approval process.
    George SL
    J Natl Cancer Inst; 2003 Sep; 95(18):1351-2. PubMed ID: 13130101
    [No Abstract]   [Full Text] [Related]  

  • 78. Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib.
    Park S; Park S; Choi H; Park JY; Lim HS; Park MJ; Kim SY
    Korean J Intern Med; 2018 Jan; 33(1):211-213. PubMed ID: 27889954
    [No Abstract]   [Full Text] [Related]  

  • 79. Myocarditis temporally related to the use of gefitinib (Iressa).
    Truell JS; Fishbein MC; Figlin R
    Arch Pathol Lab Med; 2005 Aug; 129(8):1044-6. PubMed ID: 16048398
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecule of the month. Overcoming resistance.
    Thomas AL; Lindsley CW
    Curr Top Med Chem; 2008; 8(1):62. PubMed ID: 18229423
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.